DSIP 10mg

DSIP is a synthetic peptide built from nine amino acids. The name stands for Delta Sleep-Inducing Peptide. The word delta refers to the delta-frequency waves of slow-wave sleep on an electroencephalogram — not to any Greek-letter branding — because the molecule was first identified through its capacity to enhance delta-EEG activity in animal models (PMID 265572). DSIP is one of the earliest neuropeptides to enter the sleep-research literature, and it remains one of the least understood.

The compound was isolated in the 1970s by a Basel research group studying humoral sleep factors. Investigators infused cerebral venous blood from sleep-induced rabbits into recipient animals, tracked the slow-wave-promoting fraction, and progressively purified it down to a single nine-residue sequence (PMID 560681). The final isolated molecule — a naturally occurring nonapeptide — was characterised, synthesised, and confirmed active in follow-up assays (PMID 265572). That synthetic nonapeptide is the molecule sold here.

Structurally, DSIP is a short, linear, unmodified peptide. It carries a single aromatic residue — tryptophan — at its N-terminus, two acidic residues, and a serine that can be phosphorylated. It has no disulfide bonds and coordinates no metal. The sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu condenses to the one-letter string WAGGDASGE. The CAS registry number 62568-57-4 and PubChem CID 68816 are the canonical chemical identifiers.

The compound is supplied as a lyophilized — freeze-dried — white powder in a sealed amber-glass vial under inert gas. Each vial contains 10 mg of peptide. Reconstitution with bacteriostatic water is required before the peptide can be drawn into an insulin syringe. Reconstitution mechanics are covered in the Reconstitution accordion.

Unlike the larger preclinical literatures behind compounds such as BPC-157, the DSIP research record is older, smaller, and concentrated in a handful of laboratories. Two review articles by Graf and colleagues compiled the early body of work (PMID 6145137, PMID 3550726). A later review framed the molecule honestly as a still unresolved riddle, conceding that decades of study had not pinned down a mechanism or a confirmed physiological role (PMID 16539679). Ronin presents DSIP in that honest spirit: the compound is a genuine object of scientific investigation, not a settled one.

No regulatory authority — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has cleared DSIP for therapeutic use in humans or animals. Ronin Peptides ships the compound exclusively as a research-grade reagent for benchwork. Dosing protocols, treatment regimens, and administration instructions are out of scope and are not provided in any form.

DSIP has no single established mechanism. A 2006 review summarised the state of the field bluntly, describing the molecule as an unresolved riddle decades after its discovery (PMID 16539679). The literature offers several proposed, non-exclusive mechanisms — none of them confirmed — and the honest reading is that researchers have characterised many effects without isolating a definitive receptor or pathway.

The first proposed framework is endogenous occurrence combined with central transport. This compound was isolated from the cerebral venous blood of sleep-induced rabbits, which placed it among the candidate humoral sleep factors (PMID 560681). Synthetic DSIP was reported to cross the blood-brain barrier in early transport assays, supporting the idea that a peripherally administered compound could reach central targets. The discovery context tied the compound to delta-wave EEG activity rather than to any specific signalling cascade.

A second framework involves the stress axis, and it is the clearest example of why DSIP's mechanism stays open. Graf reported that DSIP reduced corticotropin-releasing-factor-induced corticosterone release in rats, suggesting an interaction with the hypothalamic-pituitary-adrenal axis (PMID 2995861). A controlled human study, however, found that DSIP did not affect CRH- or meal-induced ACTH and cortisol secretion (PMID 7777652). The rat finding did not translate cleanly to humans — a pattern worth flagging for anyone planning new work.

A third framework points to the circadian and pineal systems. DSIP was reported to modulate the stimulation of rat pineal N-acetyltransferase activity, an enzyme central to melatonin synthesis, by involving the alpha-1-adrenergic receptor (PMID 3029331). This is one of the few papers proposing a concrete molecular handle, and it links DSIP to circadian timing rather than to a sleep on-off switch.

A fourth framework, revived in modern work, is neuroprotection. DSIP recovered motor function in rats after focal stroke in a 2021 study (PMID 34500605), and a phosphorylated DSIP variant restored spatial memory and p-CREB expression in a high-altitude model (PMID 30107169). The phosphorylated form is also relevant to pharmacokinetics: unmodified DSIP is cleaved rapidly in circulation, whereas the phospho-serine variant is more metabolically stable. None of these four frameworks excludes the others, and none has been established as the operative mechanism.

The original research stream is sleep architecture. DSIP entered the literature through delta-EEG enhancement in animal models, and the preclinical sleep work that followed examined wakefulness and sleep patterns in species including the cat (PMID 3620931). The two Graf reviews compiled this early animal-model literature alongside distribution and metabolism data (PMID 6145137). The animal findings were the basis for the compound's name, but they did not establish DSIP as a reliable sleep inducer.

Human sleep research produced mixed results, and this is the most important honesty point on the page. A double-blind study in chronic insomniac patients examined the compound's effects on sleep but did not yield a clean confirmation of benefit (PMID 1299794). A separate human study measured endogenous DSIP across normal subjects and patients with sleep apnea and narcolepsy, treating the compound as an endogenous marker rather than a confirmed therapeutic (PMID 8532601). The human literature is best described as inconclusive rather than positive, and this compound cannot be characterised as improving sleep on the available evidence.

Stress-axis research is similarly split. The positive rat result on CRF-induced corticosterone release (PMID 2995861) sits directly against the negative human result on CRH- and meal-induced ACTH and cortisol (PMID 7777652). Presenting both is the scientifically honest framing; selecting only the positive animal data would misrepresent the record.

Circadian-system research has examined DSIP's interaction with pineal enzyme activity and alpha-1-adrenergic signalling (PMID 3029331), placing it adjacent to melatonin-pathway work without establishing a causal role. A 2001 overview from the anaesthesia literature surveyed the molecule across disciplines (PMID 11437870), reflecting interest beyond the original sleep framing.

The most recent research stream is neuroprotection. A 2021 study reported motor-function recovery after focal stroke in rats (PMID 34500605), and 2018 work on phosphorylated DSIP reported restored spatial memory and improved sleep architecture in a high-altitude model (PMID 30107169). These modern papers indicate that research on the compound has not closed; it has shifted toward neural-injury and cognition models. Researchers planning new work should review the most current literature directly, with attention to the gap between the older sleep claims and the open mechanistic questions.

Unopened lyophilized vials hold up well under dry ambient storage; usable activity persists for several weeks even without refrigeration. The recommended container is the unopened original vial — keep the seal intact until reconstitution. Refrigeration at 2–8 °C is appropriate once the working timeline extends past a month. A standard freezer at −20 °C handles archival storage; ultra-low storage at −80 °C is rarely needed for typical bench-research timescales.

Keep vials shielded from light, ideally in their original outer packaging. The N-terminal tryptophan makes DSIP modestly light-sensitive in solution, since indole side chains can photo-oxidise — another reason to minimise light exposure once reconstituted. Repeated temperature cycling accelerates degradation noticeably more than steady storage at any single temperature inside the recommended bands — minimise transitions between cold and ambient.

After reconstitution, refrigerate the solution at 2–8 °C without delay. The typical working window for a reconstituted preparation is a few weeks at fridge temperature, and DSIP's short-peptide chemistry means concentration can drift faster than for more rigid sequences. Past that window, peptide concentration declines through chemical degradation pathways even though the bacteriostatic water's benzyl alcohol still suppresses microbial growth. The 0.9% benzyl alcohol holds back bacterial contamination — the dominant spoilage path — but does not arrest the slower hydrolysis, oxidation, and aggregation processes that accumulate in any aqueous peptide solution.

When a research timeline extends past the working window, common practice is splitting the reconstituted solution into single-use volumes and freezing them at −20 °C immediately. Ice-crystal formation during each freeze-thaw cycle inflicts mechanical damage on peptide chains, and pre-splitting eliminates the cumulative loss that comes from thawing one vial multiple times. Thaw individual aliquots overnight in a refrigerator — never at room temperature — and use them within a few days of thaw.

The reconstituted product should be visually clear and colourless. Discard any vial showing turbidity, suspended particulate, yellowing, or visible precipitate. The diluent of choice is USP-grade bacteriostatic water containing 0.9% benzyl alcohol — see the bacteriostatic water product page for reconstitution-grade water.

DSIP sits in Ronin's cognitive and neuro-research category alongside Selank and Semax, two better-characterised peptides with clearer proposed mechanisms. Its circadian and pineal associations also place it adjacent to Epithalon. Where Selank and Semax have relatively defined signalling frameworks, DSIP is distinguished by an unresolved mechanism — a difference researchers should weigh when selecting a compound for a given study design.

A 10 mg vial of DSIP reconstituted with 2 mL of bacteriostatic water yields a final concentration of approximately 5 mg/mL, or 5,000 mcg/mL. Other diluent volumes scale linearly: 3 mL gives roughly 3.33 mg/mL, 5 mL gives 2 mg/mL.

Reconstitution procedure:

1. Bring both vials — peptide and bacteriostatic water — to room temperature before opening.
2. Sanitise both rubber stoppers with an alcohol swab.
3. Pull the chosen diluent volume into a sterile transfer syringe.
4. Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and denatures peptide at the air-water interface.
5. Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
6. Refrigerate at 2–8 °C the moment reconstitution completes, and keep the vial shielded from light.

A finished preparation should be visually transparent with no suspended particulate. If the solution is hazy or contains visible material, treat it as degraded or contaminated and discard.

For dose-volume calculations on insulin syringes, use the Ronin peptide reconstitution calculator. The calculator converts target quantities to U-100 syringe units for any combination of vial size and diluent volume.

In published preclinical and older clinical research, DSIP has been administered across a wide range of doses and routes, reflecting the molecule's exploratory history rather than any settled protocol (PMID 6145137, PMID 3550726, PMID 1299794). Routes reported in the literature include intravenous, subcutaneous, and intraperitoneal administration in animal models, with intravenous infusion common in the early human studies. These figures are research-reference only — Ronin Peptides does not provide dosing recommendations or administration instructions for any non-laboratory purpose.

1. Schoenenberger GA et al. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977;74(3):1282-1286. PMID: 265572 | doi:10.1073/pnas.74.3.1282
2. Schoenenberger GA et al. A naturally occurring delta-EEG enhancing nonapeptide in rabbits. X. Final isolation, characterization and activity test. Pflugers Arch. 1977;369(2):99-109. PMID: 560681
3. Graf MV et al. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93. PMID: 6145137 | doi:10.1016/0149-7634(84)90023-2
4. Graf MV et al. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187. PMID: 3550726 | doi:10.1016/0196-9781(86)90148-8
5. Kovalzon VM et al. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. PMID: 16539679 | doi:10.1111/j.1471-4159.2006.03726.x
6. Pollard BJ et al. Delta sleep-inducing peptide. Eur J Anaesthesiol. 2001;18(7):419-422. PMID: 11437870 | doi:10.1046/j.1365-2346.2001.00876.x
7. Graf MV et al. Delta-sleep-inducing peptide reduces CRF-induced corticosterone release. Neuroendocrinology. 1985;41(4):353-356. PMID: 2995861 | doi:10.1159/000124200
8. Späth-Schwalbe E et al. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995;20(3):231-237. PMID: 7777652 | doi:10.1016/0306-4530(94)00058-1
9. Graf MV et al. Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. J Neurochem. 1987;48(4):1252-1257. PMID: 3029331 | doi:10.1111/j.1471-4159.1987.tb05655.x
10. Susić V et al. The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat. Brain Res. 1987;414(2):262-270. PMID: 3620931 | doi:10.1016/0006-8993(87)90006-4
11. Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. PMID: 1299794 | doi:10.1159/000118923
12. Vgontzas AN et al. Delta sleep-inducing peptide in normal humans and in patients with sleep apnea and narcolepsy. Peptides. 1995;16(6):1153-1156. PMID: 8532601 | doi:10.1016/0196-9781(95)02006-3
13. Tukhovskaya EA et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173. PMID: 34500605 | doi:10.3390/molecules26175173
14. Roy K et al. Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude. Life Sci. 2018;209:282-290. PMID: 30107169 | doi:10.1016/j.lfs.2018.08.026